Publication | Closed Access

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

Gastrointestinal OncologyMedicinePathologyMolecular OncologyCancer TreatmentOncologyRadiation OncologyCancer Research